LPL Financial
VKTX icon

LPL Financial’s Viking Therapeutics VKTX Stock Holding History

LPL Financial’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,500
Closed -$307K – 5033
2023
Q4 		$307K Hold
16,500
– – ﹤0.01% 4076
2023
Q3 		$183K Hold
16,500
– – ﹤0.01% 4277
2023
Q2 		$267K Buy
+16,500
New +$346K ﹤0.01% 3948

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

LPL Financial's VKTX Position: Q1 2026 in Review

LPL Financial reduced its Viking Therapeutics (VKTX) stake by 3.1% in Q1 2026, selling an estimated $180K and leaving 174,263 shares worth $5.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2513.

LPL Financial first reported a position in VKTX in Q1 2019 and has held it in 29 quarters since. The position peaked at $6.33M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • LPL Financial held 174,263 shares of Viking Therapeutics worth $5.67M as of Q1 2026.
  • LPL Financial sold 5,593 Viking Therapeutics shares in Q1 2026, an estimated $180K.
  • Viking Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #2513 holding.
  • LPL Financial first reported a position in Viking Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • LPL Financial's Viking Therapeutics position peaked at $6.33M in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.